Skip to main content
Home / Current Drug Targets, Volume 8, Number 2
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

Publisher: Bentham Science Publishers

More about this publication?
Volume 8, Number 2, 2007

Articles

Editorial [ Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch) ]
pp. 203-203(1)
Authors: Serve, Hubert; Carl Hasselbalch, Hans

Favourites:
ADD

Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
pp. 205-216(12)
Authors: Reiter, Andreas; Walz, Christoph; P. Cross, Nicholas C.

Favourites:
ADD

Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
pp. 217-235(19)
Authors: Morgan, M. A.; Ganser, A.; M. Reuter, C. W.

Favourites:
ADD

Oncogenic Signaling in Acute Myeloid Leukemia
pp. 237-246(10)
Authors: Brandts, Christian H.; Berdel, Wolfgang E.; Serve, Hubert

Favourites:
ADD

The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders
pp. 247-256(10)
Authors: Carl Hasselbalch, Hans; Riley, Caroline H.

Favourites:
ADD

Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
pp. 257-268(12)
Authors: Kessler, Torsten; Fehrmann, Frauke; Bieker, Ralf; Berdel, Wolfgang E.; Mesters, Rolf M.

Favourites:
ADD

Editorial [ Hot Topic: Current Drug Targets in Degenerative Joint Disease (Guest Editors: T. Aigner and E. Bartnik) ]
pp. 269-270(2)
Authors: Aigner, Thomas; Bartnik, Eckart

Favourites:
ADD

Pathobiology of Osteoarthritis: Pathomechanisms and Potential Therapeutic Targets
pp. 271-282(12)
Authors: Roach, H. I.; Aigner, T.; Soder, S.; Haag, J.; Welkerling, H.

Favourites:
ADD

Cytokine Targeting in Osteoarthritis
pp. 283-292(10)
Authors: Blom, Arjen B.; van der Kraan, Peter M.; van den Berg, Wim B.

Favourites:
ADD

Molecular Targets in Osteoarthritis: Metalloproteinases and Their Inhibitors
pp. 293-303(11)
Authors: Burrage, P. S.; Brinckerhoff, C. E.

Favourites:
ADD

Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis
pp. 305-313(9)
Author: Saklatvala, Jeremy

Favourites:
ADD

Role of Cathepsin K in Normal Joints and in the Development of Arthritis
pp. 315-323(9)
Authors: Salminen-Mankonen, H. J.; Morko, J.; Vuorio, E.

Favourites:
ADD

Osteoarthritis: Aging of Matrix and Cells - Going for a Remedy
pp. 325-331(7)
Authors: Aigner, T.; Haag, J.; Martin, J.; Buckwalter, J.

Favourites:
ADD

Cell Death and Apoptosis in Ostearthritic Cartilage
pp. 333-345(13)
Authors: Kim, H. A.; Blanco, F. J.

Favourites:
ADD

Antioxidant to Treat Osteoarthritis: Dream or Reality?
pp. 347-357(11)
Authors: Henrotin, Y.; Kurz, B.

Favourites:
ADD

Anabolic Factors in Degenerative Joint Disease
pp. 359-365(7)
Author: Sandell, L. J.

Favourites:
ADD

In Vivo Osteoarthritis Target Validation Utilizing Genetically-Modified Mice
pp. 367-376(10)
Author: Glasson, Sonya S.

Favourites:
ADD

Growth Plate Cartilage as Developmental Model in Osteoarthritis Research -Potentials and Limitations
pp. 377-385(9)
Authors: Aigner, T.; Gerwin, N.

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content